Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

A Phase I, Open Label, First In Humans (FIH), Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

This Phase I clinical trial will evaluate the safety, tolerability, and immunogenicity of 4 mg doses of ITI-3000 in participants with polyomavirus-positive Merkel cell carcinoma (MCC).

Study Overview

• Status: Completed
• Conditions: Merkel Cell Carcinoma
• Intervention / Treatment: Drug: ITI-3000

Detailed Description

This is a single dose design examining 4 mg dose of the DNA vaccine ITI-3000 in participants who were diagnosed with polyomavirus-positive MCC, histologically confirmed by an expert pathologist on standard clinical staining, that may have been supplemented by specific staining for Cytokeratin 20 (CK20) and/or other markers used to distinguish MCC.

Evidence of Merkel cell polyomavirus (MCPyV) in the tumor at initial presentation (pre-therapy) can be provided by a positive anti-MCPyV oncoprotein antibody AMERK Test.

Participants in the study are those who are both diagnosed and have completed standard of care (SOC) surgical and/or radiation therapy at least 1 year prior to enrollment in the study and have no evidence of active disease (NEAD). Participants those who were previously diagnosed with MCC, and had recurrence and also exhibited no evidence of active disease (NEAD) for more than 2 years prior to enrollment in the study.

NEAD is confirmed by physical examination, a negative AMERK test (<74 STU) in participants with a prior positive AMERK test, or significantly decreased, stable AMERK titers in 2 or more consecutive draws compared to prior positive AMERK test at the time of diagnosis, in the setting of a negative computed tomography (CT) scan of the chest, abdomen and pelvis or PET-CT within 3 months of enrollment into the study.

Eight participants will be enrolled at 4 mg total DNA dose to assess safety, tolerability, and immunologic response to the ITI-3000 vaccine.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Veronica Gonzalez; Phone Number: 1-301-968-3501; Email: vgonzalez@immunomix.com
• Study Contact Backup: Name: Elizabeth Walsh; Phone Number: 1-301-968-3501; Email: ewalsh@immunomix.com

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98109
      • University of Washington/Seattle Cancer Care Alliance

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Evidence of Merkel cell polyomavirus (MCPyV) in the tumor at initial presentation (pre-therapy) can be provided by a positive anti-MCPyV oncoprotein antibody AMERK Test.
• Eligible participants have to be both be diagnosed and have completed SOC surgical and/or radiation therapy at least 1 year prior to enrollment in the study and have no evidence of active disease (NEAD).
• Participants who were previously diagnosed with MCC and had recurrence and also exhibited no evidence of active disease (NEAD) for more than 2 years prior to enrollment in the study.
• Age ≥ 18 years.
• Karnofsky performance status (PS) ≥ 70 or ECOG PS 0-1.
• Participant has a predicted life expectancy ≥ 3 months.
• Participant provided signed and dated informed consent prior to initiation of any study procedures.
• Participant has adequate renal function (creatinine ≤ 1.5 times the upper limit of normal [ULN]) or a glomerular filtration rate (GFR) of ≥ 50 mL/min/1.73 m2).
• Participant has adequate hepatic function, as evidenced by a total bilirubin ≤ 1.5 times the ULN, aspartate transaminase (AST), and/or alanine transaminase (ALT) ≤ 3 times the ULN.
• Participant has adequate bone marrow function, as evidenced by hemoglobin ≥ 9.0 g/dL in the absence of transfusion within the previous 72 hours, platelet count ≥ 100×109cells/L, and absolute neutrophil count (ANC) ≥ 1.5×109 cells/L.

• Participant and his/her partner agree to use adequate contraception after providing written informed consent through 2 months after the last study drug dose, as follows:

  • For women: Negative pregnancy test during Screening and at Baseline and compliant with two methods of medically-approved contraceptive regimens or abstinence during and for 2 months after the treatment period or documented to be surgically sterile or postmenopausal.
  • For men: Compliant with two methods of medically approved contraceptive regimens or abstinence during and for 2 months after the treatment period or documented to be surgically sterile
• Participant is willing and able to participate in the study and comply with all study requirements.

Exclusion Criteria:

• Participation in another therapeutic clinical trial.
• Participant who received systemic treatment previously (e.g., chemotherapy, PD-1/PD-L1).
• Participant is pregnant or breast-feeding.
• Negative for an anti-MCPyV oncogene antibody titer or other evidence of no MCPyV involvement at initial presentation using an acceptable and specific assay at the institution.
• Known history of AIDS/HIV, other viral diseases or oncologic disorders such as untreated HCV, chronic active HBV or organ transplantation that may have immunologic consequences or require immunosuppression. No testing required.
• Participant with CLL-associated MCC.
• On-going immunosuppressive therapy for other conditions with the exception of low-dose topical, nasal or inhaled steroids.
• Participant has a history of other malignancy treated with curative intent within the previous 3 years with the exception of adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix. Participants with previous invasive cancers are eligible if the treatment was completed more than 3 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
• Participant has a significant medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.
• Participant with otherwise unexplained >10% weight loss in the last 30 days prior to the screening.
• Participant has evidence of serious active infection (i.e., infection requiring treatment with intravenous antibiotics).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Participants With Polyomavirus-Positive Merkel Cell Carcinoma (MCC); Eight participants with MCC (> 1.0 years since definitive treatment or participants who had recurrence >2 years since evidence of disease) and NEAD	Drug: ITI-3000; ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with Dose Limiting Toxicities (DLTs).	Number of participants that experience any Dose Limiting Toxicities (DLTs).	Through study completion, up to 12 months.
Number of occurrences of Adverse events/Serious Adverse Events that will be assessed for severity according to the NCI CTCAE, version 5.0.	Number of occurrences of Adverse events/Serious Adverse Events that will be assessed for severity according to the NCI CTCAE, version 5.0.	Through study completion, up to 12 months.
Number of participants with changes from baseline in physical exam findings.	Number of participants with changes from baseline in physical exam (e.g. weight, height, etc.) findings.	Through study completion, up to 12 months.
Number of participants with changes from baseline in hematology lab results.	Number of participants with changes from baseline in hematology lab results (e.g. Hgb, PLT CT, Hct, RBC, etc.).	Through study completion, up to 12 months.
Number of participants with changes from baseline in chemistry lab results.	Number of participants with changes from baseline in chemistry lab results (e.g. Alb, ALK, CO2, BUN, Glu,etc.) .	Through study completion, up to 12 months.
Number of participants with changes from baseline in urinalysis lab results.	Number of participants with changes from baseline in urinalysis lab results (e.g. SPG, pH, TP, Glu, etc.) .	Through study completion, up to 12 months.
Number of participants with changes from baseline vital signs.	Number of participants with changes from baseline vital signs (e.g. body temp, BP, RR, etc.) .	Through study completion, up to 12 months.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory endpoints include immune assessments for anti-MCPyV T-cell response	Changes in titers from baseline.	Through study completion, up to 12 months.
Exploratory endpoints include immune assessments anti- MCPyV LT antibodies	Changes in titers from baseline.	Through study completion, up to 12 months.
Exploratory endpoints include immune assessments for anti-MCPyV oncoprotein antibodies	Changes of anti-MCPyV oncoprotein antibodies from baseline.	Through study completion, up to 12 months.

Collaborators and Investigators

• Sponsor: Immunomic Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 13, 2022
• Primary Completion (Actual): June 27, 2023
• Study Completion (Actual): June 27, 2023

Study Registration Dates

• First Submitted: June 1, 2022
• First Submitted That Met QC Criteria: June 14, 2022
• First Posted (Actual): June 16, 2022

Study Record Updates

• Last Update Posted (Actual): November 22, 2023
• Last Update Submitted That Met QC Criteria: November 21, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Virus Diseases; Infections; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; DNA Virus Infections; Tumor Virus Infections; Neuroendocrine Tumors; Polyomavirus Infections; Carcinoma, Neuroendocrine; Carcinoma; Carcinoma, Merkel Cell
• Other Study ID Numbers: ITI-3000

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No